Gene-drug interactions (data source: DGIdb)
Gene Name Entrez ID Drug Name Chembl ID Interaction Types Sources publications
HINT1 3094 MESALAMINE CHEMBL704 DrugBank 17139284, 17016423, 10592235
HINT1 3094 CHEMBL283807 CHEMBL283807 DrugBank 17139284, 17016423, 10592235
HINT1 3094 CHEMBL1230617 CHEMBL1230617 DrugBank 17139284, 17016423, 10592235
HINT1 3094 ADENOSINE PHOSPHATE CHEMBL752 product of DrugBank 17217311, 17158446, 17337452

Variant-drug associations (data source: PharmGKB)
Gene Name Variant Alleles Chemical Phenotype Category Significance Notes Sentence Publications Annotation ID
HINT1 rs3852209 CT + TT nicotine efficacy yes Bivariate and multivariate analysis showed that significantly more patients with the CT or TT genotypes were abstinent from nicotine at 6 months after ending nicotine replacement therapy. However, no significant association was found using bivariate or multivariate analysis at the end of nicotine replacement therapy treatment. Genotypes CT + TT are associated with increased response to nicotine in people with Tobacco Use Disorder as compared to genotype CC. 17978999 1450811453
HINT1 rs3864283 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714533
HINT1 rs3852209 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele T. 21398039 1449714519
HINT1 rs2551038 C opioids dosage no Variant had no significant association with opioid dose in either the development sample or the validation sample. Allele C is not associated with dose of opioids in people with Pain as compared to allele G. 21398039 1449714526
HINT1 rs2278060 AC + CC nicotine efficacy no Bivariate and multivariate analysis showed no significant association between the genotypes and abstinence from smoking at the end of nicotine replacement therapy treatment or 6 months after completing treatment. Genotypes AC + CC are not associated with response to nicotine in people with Tobacco Use Disorder as compared to genotype AA. 17978999 1450811465